In their final thoughts, Drs Brinton, Baum and Michos provide insights on the trajectory of treatment in HoFH. Eliot Brinton, MD: One of the questions that often comes up in the process of diagnosing ...
Medical experts discuss the unmet needs surrounding homozygous FH. Eliot Brinton, MD: With all the tools we have for homozygous familial hypercholesterolemia [HoFH], there are patients who spend way ...
Do you know your LDL? It's the bad cholesterol in our bodies and the American Heart Association says keeping it under 100 is best to avoid heart attacks and strokes, but for some people no matter what ...
LIBerate-HoFH study was part of a global registration-enabling Phase 3 program of > 2,900 patients Biologics license application for lerodalcibep submitted to FDA in December 2024 ...
MANNHEIM, Germany—Response to treatment is highly variable with the investigational PCSK9 inhibitor lerodalcibep (LIB Therapeutics), as well as with evolocumab (Repatha; Amgen), in patients who have ...
London, UK - The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that the lomitapide preparation Lojuxta (Aegerion Pharmaceuticals) be ...
HoFH is a rare genetic condition that leads to extremely high levels of low-density lipoprotein cholesterol (LDL). Credit: Kitsawet Saethao/Shutterstock. · Clinical Trials Arena · Kitsawet ...
Please provide your email address to receive an email when new articles are posted on . Regeneron Pharmaceuticals announced the FDA has extended approval of evinacumab-dgnb as an adjunct to other ...
Regeneron Pharmaceuticals, Inc.REGN presented positive phase II data, evaluating its investigational angiopoietin-like 3 (ANGPTL3) antibody, evinacumab at the National Lipid Association's (NLA) ...
The approval of Repatha was also expanded to include patients 10 years of age and older with HoFH. The Food and Drug Administration (FDA) has approved Repatha (evolocumab) injection as an adjunct to ...
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results